Although headquartered in the UK, AstraZeneca is still known as the 'Anglo-Swedish pharma company', having been created from the merger of the British Zeneca and Sweden's Astra in 1999.

Goldman Sachs analyst Rajan Sharma maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £155.58. The ...